Evidence map›Paper›PMID 42022489›Full record

ArticleJCEM case reports2026

Late recurrent renal cell carcinoma presenting as a solitary gallium-68 DOTATATE-avid pancreatic mass with polycythemia.

Mohamed Albalawi, Ur Metser, Shereen Ezzat

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohamed AlbalawiEndocrine Oncology Site Group, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada M5G-2M9.ORCID https://orcid.org/0009-0007-4612-9861
Ur MetserJoint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, Canada M5G-2M9.ORCID https://orcid.org/0000-0003-3726-8994
Shereen EzzatEndocrine Oncology Site Group, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada M5G-2M9.ORCID https://orcid.org/0000-0002-0715-6898

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic metastasis of renal cell carcinoma (RCC) is rare and can present many years after nephrectomy. It can exhibit radiological characteristics very similar to those of a pancreatic neuroendocrine tumor (pNET). Here, we present a case of an 81-year-old female who presented with an incidentally discovered solitary hypervascular pancreatic head mass with intense gallium-68-DOTA-OCTREOTATE positron emission tomography/computed tomography (Ga-68 DT-PET/CT) uptake 15 years after her initial nephrectomy for an RCC. The mass continued to grow despite somatostatin analog (SSA) therapy, prompting endoscopic ultrasound (EUS)-guided biopsy, which revealed metastatic RCC.

Indexed as

gallium-68 dotatate positron emission tomographymetastatic renal cell carcinomapancreatic neuroendocrine tumorpolycythemia

Identifiers

PMID42022489
PMCPMC13097129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.